0HF9 Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0HF9 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.51 |
| 52 Week High | US$14.01 |
| 52 Week Low | US$8.79 |
| Beta | 0.61 |
| 1 Month Change | 1.37% |
| 3 Month Change | -0.013% |
| 1 Year Change | -29.72% |
| 3 Year Change | 13.13% |
| 5 Year Change | n/a |
| Change since IPO | -41.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HF9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.8% | -0.7% | -0.2% |
| 1Y | -29.7% | -11.5% | 10.8% |
Return vs Industry: 0HF9 underperformed the UK Biotechs industry which returned -11.5% over the past year.
Return vs Market: 0HF9 underperformed the UK Market which returned 10.8% over the past year.
Price Volatility
| 0HF9 volatility | |
|---|---|
| 0HF9 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HF9 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HF9's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
| 0HF9 fundamental statistics | |
|---|---|
| Market cap | US$2.94b |
| Earnings (TTM) | -US$104.69m |
| Revenue (TTM) | US$493.67m |
6.0x
P/S Ratio-28.1x
P/E RatioIs 0HF9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HF9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 89.99% |
| Net Profit Margin | -21.21% |
| Debt/Equity Ratio | 217.8% |
How did 0HF9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 23:09 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amicus Therapeutics, Inc. is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Michael Ulz | Baird |
| Yun Zhong | Berenberg |